Most patients in the United States are now diagnosed for cystic fibrosis (CF) through newborn screening (NBS) and use of molecular testing methods. This article reviews the molecular testing approaches and laboratory guidelines for carrier screening, prenatal testing, NBS, and clinical diagnostic testing, as well as recent developments in CF treatment, and reasons for the lack of a molecular diagnosis in some patients.